Identification of a Novel Series of Bet Family Bromodomain Inhibitors: Binding Mode and Profile of I-Bet151 (Gsk1210151A).
Seal, J., Lamotte, Y., Donche, F., Bouillot, A., Mirguet, O., Gellibert, F., Nicodeme, E., Krysa, G., Kirilovsky, J., Beinke, S., Mccleary, S., Rioja, I., Bamborough, P., Chung, C., Gordon, L., Lewis, T., Walker, A.L., Cutler, L., Lugo, D., Wilson, D.M., Witherington, J., Lee, K., Prinjha, R.K.(2012) Bioorg Med Chem Lett 22: 2968
- PubMed: 22437115 
- DOI: https://doi.org/10.1016/j.bmcl.2012.02.041
- Primary Citation of Related Structures:  
4AKN, 4ALG - PubMed Abstract: 
A novel series of quinoline isoxazole BET family bromodomain inhibitors are discussed. Crystallography is used to illustrate binding modes and rationalize their SAR. One member, I-BET151 (GSK1210151A), shows good oral bioavailability in both the rat and minipig as well as demonstrating efficient suppression of bacterial induced inflammation and sepsis in a murine in vivo endotoxaemia model.
Organizational Affiliation: 
Epinova DPU, GlaxoSmithKline R&D, Medicines Research Centre, Stevenage, Hertfordshire, UK. jon.t.seal@gsk.com